mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery

International Journal of Medical, Pharmacy and Drug Research (IJMPD)
[Vol-6, Issue-2, Mar-Apr, 2022]
ISSN: 2456-8015
https://dx.doi.org/10.22161/ijmpd.6.2.7
Peer-Reviewed Journal
Int. J. Med. Phar. Drug Re. 2022 52
Vol-6, Issue-2; Online Available at: https://www.aipublications.com/ijmpd/
mRNA vaccines against emerging infectious diseases; A
challenging approach of novel vaccine discovery
Mr. Utkalendu Suvendusekhar Samantaray1
, Rudra Prasad Khuntia2
1
BSc MSc, Utkal University, Bhuaneswar, Odisha, India
utkalgenome@gmail.com
2
BSc MSc, Sikhsha 'O' Anusandhan University, Bhubaneswar, Odisha, India
Received: 01 Apr 2022; Received in revised form: 22 Apr 2022; Accepted: 27 Apr 2022; Available online: 30 Apr 2022
©2022 The Author(s). Published by AI Publications. This is an open access article under the CC BY license
(https://creativecommons.org/licenses/by/4.0/)
Abstract— Basic human biology is dealt with by mRNA, which creates instructions for making proteins that
may aid in the fight against infectious illnesses using our bodies' own mechanisms. mRNA therapies are
neither tiny compounds nor huge biological such as recombinant proteins or monoclonal antibodies. These
are a series of instructions that assist our cells' machinery in producing proteins that protect us against a
certain virus. Our bodies would be unable to perform their activities if mRNA was not introduced. mRNA, or
messenger ribonucleic acid, is an important component of the living world, especially in the process of
protein synthesis. mRNA is a single-stranded molecule that transmits genetic instructions from a cell's
nucleus DNA to the ribosomes, which are the cell's protein-making machinery. The synthesis of an RNA copy
from the coded sequence of DNA leads in the production of a particular protein. This copy of mRNA moves
from the nucleus of the cell to the cytoplasm, where ribosomes reside. Ribosomes are a sort of sophisticated
machinery organelle that aids and begins protein synthesis in cells. Ribosomes ‘read' the mRNA sequence
and follow the instructions, progressively adding on various needed amino acids to make the intended protein
during the translation process. The protein is subsequently expressed by the cell, and it goes on to execute
its role in the cell or in the body. The use of mRNA as a medication offers up a whole new universe of
possibilities in terms of illness treatment and prevention. This review contributes to the growing body of
knowledge in the field of mRNA therapeutic delivery and the identification of appropriate antigens for mRNA
target locations. Two major mRNA vaccines for protection against SARS-CoV-2 have recently been
developed and approved for use in the general population by international health authorities. They've been
demonstrated to defend against the SARS-CoV-2 virus, which is still active and evolving. This will draw
attention to a variety of mRNA vaccines now being evaluated for infectious diseases in clinical studies. mRNA
vaccines offer a number of advantages, including speedy design, fabrication, manufacturing, and
administration, and they hold a lot of potential for future use against a wide range of diseases.
Keywords— mRNA vaccines, SARS-CoV-2, DNA.
I. INTRODUCTION TO MRNA
A single-stranded RNA molecule that matches the
genetic sequence of a gene and is read by a ribosome during
the protein synthesis process is known as messenger
ribonucleic acid (mRNA). mRNA medications can directly
trigger protein creation within the cytosol, unlike other
pharmacological techniques that cannot get inside cells to
direct protein production. They have the potential to cure or
prevent illnesses that are now incurable, ultimately
enhancing human health and having a global effect. mRNA
vaccines are a viable alternative to conventional vaccination
techniques because of their great potential for rapid
development, low-cost manufacture, and safe delivery. the
recent technological developments, of multiple mRNA
vaccination systems against infectious diseases and a
variety of cancers, have demonstrated promising results in
both animal models and humans. This Review, like that of

Samantaray et al./ mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery
recombinant DNA medicines, looks at the opportunities and
challenges of bringing this potential vaccine platform into
widespread therapeutic use. They combine the ability of
mRNA to encode practically any protein with a high level
of safety and a flexible manufacturing method.
Over the past decade, mRNA vaccines have grown
in popularity as a flexible tool for developing novel creative
therapies, not only in infectious illness settings but also in
cancer. An mRNA vaccine is traditionally made up of a
messenger RNA synthesized in vitro using a bacteriophage
RNA polymerase and a template DNA encoding the
antigen(s) of interest. After being given and internalized by
host cells, mRNA transcripts are immediately found in the
cytoplasm of the cell. Antigens produced by the cell are
subsequently delivered to immune system cells, triggering
an immunological response. Dendritic cells may be
employed as a carrier by loading their cytoplasm with
tumor-associated antigen mRNAs or total tumor RNA, then
delivering the mRNA-loaded dendritic cells to the host to
trigger a particular immune response. Two mRNA vaccines
for COVID-19 infection prevention were recently licensed
for human use, creating enthusiasm about the future
prospects of this method for cancer immunotherapy and
other infectious disease prevention. The increased demand
for mRNA vaccines needs the creation of a technological
platform as well as a cost-effective production method with
well-defined product features. In the large-scale
manufacture of mRNA vaccines, a single or two-step in
vitro reaction is followed by a purification platform with
numerous phases that might involve DNase digestion,
precipitation, chromatography, or tangential flow filtering.
To create mRNA vaccines, the encoded antigen is placed
into a DNA template, from which the mRNA is generated
in vitro. In contrast to DNA, mRNA simply needs to enter
the cytoplasm in order to be transcribed into antigen by the
cell machinery in vivo. This method allows any desired
sequence to be created, synthesized in vitro, and given to
any cell type. Endosomal or cytosolic receptors in the cells
recognize RNA, which activates the type I interferon (IFN-
I) pathway and promotes the production of chemokines and
proinflammatory cytokines. These signal molecules
stimulate antigen-presenting cells (APCs), resulting in a
powerful adaptive response. The creation of mRNA, which
is done in a cell-free environment, does not involve any
animal-derived raw materials. As a consequence, there are
no contaminants or contaminations originating from cells,
making the manufacturing of these compounds safer.
Because it does not need the utilization of cell cultures,
mRNA synthesis is more cost-effective than other
biological processes. Because of the short response time, the
danger of contamination is smaller than with other
sophisticated vaccine production techniques.
II. DELIVERY OF MRNA VACCINES
Since mRNA antibodies are intrinsically delicate, their
organization is basic. Intravenous infusion of unmodified
mRNA expands the inborn safe reaction by making it be
processed by ribonucleases. mRNA circulation ought to
enact safe framework cells, for example, antigen-
introducing cells (APCs), B cells, and T cells. Since mRNA
particles are multiple times greater than different atoms,
conveying them is troublesome. Besides, since mRNA is
adversely charged, it is repulsed by the cell film. This
obstruction could be overwhelmed by utilizing adjusted
RNA and further developed conveyance frameworks.
mRNA stages have been made utilizing lipid nanoparticles
and protamine, dendrimers, polyethyleneimine. Lipid
nanoparticles (LNP) are lipid nanoparticles that include
nucleoside changed nucleoside Phospholipids, cholesterol,
ionizable lipids, and lipid-moored polyethylene glycol
(PEG). Cytoplasmic conveyance, cell take-up, and
endosomal take-up are completely improved by LNPs. By
impeding mRNA from being distinguished by endosomes
and cost-like receptors, LNPs likewise keep the natural
invulnerable framework from becoming overactive (TLRs).
A few mRNA immunizations have adjuvant properties,
which could be useful. mRNAs can be changed to advance
safe enactment without compelling mRNA articulation.
One example is the modification of a nucleoside with the
TLR-4 agonist monophosphorylate lipid A (MPLA), which
aids T cell activation. A short stretch of the double-stranded
region in the poly-A tail or 3UTR of mRNA is also used as
a method. The insertion of a short poly U or poly-A tail
increases dendritic cell activation and migration by inducing
IFN-B and IL-6. TLR3 and RIG-I both identify the ds poly
U or poly-A tail. Two SARS-CoV-2 RNA lipid nanoparticle
vaccines were recently developed using nucleoside
modified mRNA (modRNA). BNT162b1 is a modRNA
with a reduced ability to activate immunological sensors
and increased RBD expression. 41 BNT162b2 is a P2
mutant, perfusion spike glycoprotein-expressing modRNA
vaccine (P2S).
III. IMMUNE RESPONSE TO MRNA
VACCINES
The immune response to the mRNA vaccine is being studied
right now. RIG-I-like receptors and TLRs are two kinds of
RNA sensors distinguished in people. TLR7, TLR3, TLR9,
and TLR8 are four TLRs found in macrophages, monocytes,
and dendritic cells, separately. TLR3 can differentiate
between twofold abandoned RNA (dsRNA) and single-
abandoned RNA (sRNA) (ssRNA). TLR7 perceives both
ssRNA and dsRNA, while TLR8 perceives just ssRNA.
RIG-I, MDA-5, and LGP2 are all RIG-I relatives. By

recognizing ssRNA and dsRNA, RIG-I helps interferon
creation. MDA5 is a cytosolic RNA sensor that recognizes
long twofold abandoned RNA that is made during viral
RNA replication. IRF-3 and NF-KB are enacted because of
the recognizable proof of ds RNA, and IFN-I creation is
improved. Interferon (IFN) acceptance utilizing mRNA
immunizations is subject to the in vitro interpreted mRNA,
infusion course, and conveyance vehicle. Design
acknowledgment receptors (PRRs) are actuated after
mRNA vaccination, and type I IFN creation is expanded.
IFN creation might be positive or negative contingent upon
whether the resistant reaction is initiated or mRNA
interpretation is obstructed.
IV. VACCINE-INDUCED IMMUNITY
Rather than a humoral safe reaction that kills the infection,
a cell insusceptible reaction like cytotoxic T lymphocytes
(CTLs) straightforwardly targets virally tainted cells. How
much counter acting agent not entirely set in stone by the
size of LNPs that are conveyed to depleting lymph hubs and
enact B cells. B cells might consume mRNA-containing
LNPs, permitting the mRNA to be converted into protein.
Besides, B cells have B cell receptors that express
unfamiliar antigens. B cells in depleting lymph hubs (which
contain LNP-mRNA) produce explicit low-liking
antibodies, and a portion of these antibodies might arrive at
a germinal community (GC). In B cells that enter GC,
substantial hypermutation (SHM) and proclivity
development result. Partiality created B cells produce high-
liking antibodies subsequent to becoming plasmablasts.
They may be that as it may, reappear GCs after SHM and
structure memory B cells. For successful CTL induction, the
antigen must enter the antigen processing pathway. After
then, the pathogenic antigens are carried to the cytosol and
digested by proteasomes. The peptides produced by the
proteasomal pathway are subsequently delivered to the
endoplasmic reticulum (ER) by the antigen processing
transporter (TAP). These peptides bind to the major
histocompatibility complex (MHC) class I in the ER
(MHC). CD8 T lymphocytes then recognize the MHC I-
antigen peptide complex on the cell surface. mRNA-based
vaccines are particularly well suited to inducing robust CTL
responses because they can express the antigen in the
cytoplasm of antigen-presenting cells.
V. ANTIGEN SELECTION
Several issues, such as the antigen selection for vaccination,
vaccine routes, vaccination area, and regimen, must be
considered while creating mRNA-based vaccines. Antigen
selection is an important stage in vaccine development. The
structural proteins in SARS-CoV-2 include S protein, N
protein, matrix protein (M), and envelope protein (E). The
covering of the vast positive-strand RNA genome contained
in a lipid envelope produced from the host cell membrane is
the responsibility of N protein. The proteins S, E, and M are
introduced into this membrane. Only antibodies against the
S protein have been identified to neutralize the virus and
prevent infection in SARS-CoV-2. As a result, the majority
of SARS-CoV-2 vaccines target the S1 domain of the
receptor-binding domain.
VI. ADVANTAGES AND CHALLENGES
ASSOCIATED WITH MRNA VACCINES
mRNA does not integrate into the genome; mRNA vaccines
are favorable. Incorporating changed nucleosides into the
mRNA sequence also decreases its inflammatory potential.
As a result, mRNA-based vaccinations are less dangerous
than virus-based immunizations. mRNA-based vaccines
provide various advantages over traditional vaccinations,
including precision, the ability to express just a certain
antigen, and the ability to produce a targeted immune
response. These vaccines stimulate the innate immune
system and enhance both humoral and cellular
immunological responses. Because mRNA expression in
the body does not need nuclear entrance, genomic
integration is less likely. Following the activation of an
immunological response, mRNA is rapidly destroyed by
cellular mechanisms. Because a change in the antigen has
no effect on the physical-chemical features of the mRNA
backbone, mRNA vaccine production may be readily
standardized. Furthermore, since the synthesis is based on
an in vitro cell-free transcription process, the risk of viral
contamination is decreased. mRNA vaccines have various
advantages, but they also have certain drawbacks. There is
currently no well-established manufacturing platform for
the synthesis of mRNA, necessitating a number of different
manufacturing stages. can be divided into two categories.
Furthermore, the need for cold chain storage of mRNA
vaccines presents logical challenges. There is a result, the
development of thermostable mRNA vaccines for warm
countries or those without a compatible cold storage system
is required.
VII. CONCLUSION REMARKS
In spite of the way that mRNA vaccines have been around
for very nearly thirty years, the FDA endorsed them for use
in serious patients during the SARS-CoV-2 pandemic. The
molecular mechanism of activity of mRNA antibodies
should be perceived. Nonstop improvement of UTRs and
coding mRNA will expand the immunization's security and
strength as far as antigen creation in the body. Besides, base
or sugar alterations can be utilized to work on the

dependability of mRNA immunizations, bringing about
better translational properties. The advancement of
ionizable lipids and details, as well as worked on cell take-
up, endosomal delivery, and strength, are on the whole
helpful upgrades to transporter frameworks. For
arrangement streamlining of coding mRNA successions,
bioinformatics instruments can be utilized. These devices
can likewise assist with foreseeing the connection among
preclinical and clinical mRNA immunization studies. The
objective of the present mRNA antibodies is to augment
immunogenicity and adequacy while additionally checking
immunization security in people. Resistant reaction
actuation can be advantageous, yet it can likewise prompt
entanglements. Subsequently, there is a need to advance
antibody portion titers, which requires the plan of clinical
preliminaries in a manner that actually catches the
insusceptible reaction. To distinguish these invulnerable
reactions, an assortment of advances, for example,
transcriptomics and proteomics-based approaches can be
utilized. The humoral reaction evoked by mRNA
immunizations has up until this point been substandard than
that inspired by live lessened inoculations. Thus, a careful
examination is important to foster details that would permit
the proper immunological reactions to be accomplished.
Regulatory measures for the clinical improvement of
mRNA antibodies are presently being concluded. Rules for
the examination of new transporters of mRNA antibodies,
as well as their security and adequacy, should be created.
REFERENCES
[1] Magini D, Giovani C, Mangiavacchi S, et al. Self-amplifying
mRNA vaccines expressing multiple conserved influenza
antigens confer protection against homologous and
heterosubtypic viral challenge. PLoS One.
2016;11:e0161193. doi:10.1371/journal.pone.0161193
[2] Brazzoli M, Magini D, Bonci A, et al. Induction of broad-
based immunity and protective efficacy by self-amplifying
mRNA vaccines encoding influenza virus hemagglutinin. J
Virol. 2016;90:332–344. doi:10.1128/JVI.01786-15
[3] McCullough KC, Bassi I, Milona P, et al. Self-replicating
replicon-RNA delivery to dendritic cells by Chitosan-
nanoparticles for translation in vitro and in vivo. Mol Ther
Nucleic Acids. 2014;3:e173. doi:10.1038/mtna.2014.24
[4] Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM
® vaccine against H7N9 influenza is immunogenic in mice.
Emerg Microbes Infect. 2013;2:e52.
doi:10.1038/emi.2013.54
[5] Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine
encoding rabies virus glycoprotein induces protection against
lethal infection in mice and correlates of protection in adult
and newborn pigs. PLoS Negl Trop Dis. 2016;10:e0004746.
doi:10.1371/journal.pntd.0004746
[6] Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and
immunogenicity of a mRNA rabies vaccine in healthy adults:
an open-label, non-randomised, prospective, first-in-human
phase 1 clinical trial. Lancet. 2017;390:1511–1520.
doi:10.1016/S0140-6736(17)31665-3
[7] Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ.
Developing mRNA-vaccine technologies. RNA Biol.
2012;9:1319–1330. doi:10.4161/rna.22269
[8] Andries O, Mc Cafferty S, De Smedt SC, et al. N(1)-
methylpseudouridine-incorporated mRNA outperforms
pseudouridine-incorporated mRNA by providing enhanced
protein expression and reduced immunogenicity in
mammalian cell lines and mice. J Control Release.
2015;217:337–344. doi:10.1016/j.jconrel.2015.08.051
[9] Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA
vaccines. Adv Drug Deliv Rev. 2021;170:83–112.
doi:10.1016/j.addr.2020.12.014
[10] Perri S, Greer CE, Thudium K, et al. An alphavirus replicon
particle chimera derived from Venezuelan equine
encephalitis and sindbis viruses is a potent gene-based
vaccine delivery vector. J Virol. 2003;77:10394–10403.
doi:10.1128/JVI.77.19.10394-10403.2003
[11] Fleeton MN, Chen M, Berglund P, et al. Self-replicative RNA
vaccines elicit protection against influenza A virus,
respiratory syncytial virus, and a tickborne encephalitis virus.
J Infect Dis. 2001;183:1395–1398. doi:10.1086/319857
[12] Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-
amplifying RNA vaccines. Proc Natl Acad Sci U S A.
2012;109:14604–14609. doi:10.1073/pnas.1209367109
[13] Bogers WM, Oostermeijer H, Mooij P, et al. Potent immune
responses in rhesus macaques induced by nonviral delivery of
a self-amplifying RNA vaccine expressing HIV type 1
envelope with a cationic nanoemulsion. J Infect Dis.
2015;211:947–955. doi:10.1093/infdis/jiu522
[14] Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-
specific cytotoxic T lymphocytes in vivo by liposome-
entrapped mRNA. Eur J Immunol. 1993;23:1719–1722.
doi:10.1002/eji.1830230749
[15] Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of
in vitro synthesized, specific mRNA vaccines against
influenza A virus infection. Nat Biotechnol. 2012;30:1210–
1216. doi:10.1038/nbt.2436
[16] Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1
gag specific immune responses by cationic micelles mediated
delivery of gag mRNA. Drug Deliv. 2016;23:2596–2607.
doi:10.3109/10717544.2015.1038856
[17] Li M, Zhao M, Fu Y, et al. Enhanced intranasal delivery of
mRNA vaccine by overcoming the nasal epithelial barrier via
intra- and paracellular pathways. J Control Release.
2016;228:9–19. doi:10.1016/j.jconrel.2016.02.043
[18] Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery
to dendritic cells exploits antiviral defence for cancer
immunotherapy. Nature. 2016;534:396–401.
doi:10.1038/nature18300
[19] Linares-Fernandez S, Lacroix C, Exposito JY, Verrier B.
Tailoring mRNA vaccine to balance innate/adaptive immune
response. Trends Mol Med. 2020;26:311–323.
doi:10.1016/j.molmed.2019.10.002
[20] Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical
demonstration of immunogenicity by mRNA vaccines

against H10N8 and H7N9 influenza viruses. Mol Ther.
2017;25:1316–1327. doi:10.1016/j.ymthe.2017.03.035
[21] Guevara ML, Persano F, Persano S. Advances in lipid
nanoparticles for mRNA-based cancer immunotherapy. Front
Chem. 2020;8:589959. doi:10.3389/fchem.2020.589959
[22] Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid
nanoparticle structure for messenger RNA delivery. Nano
Lett. 2020;20:4543–4549. doi:10.1021/acs.nanolett.0c01386
[23] Reichmuth AM, Oberli MA, Jaklenec A, Langer R,
Blankschtein D. mRNA vaccine delivery using lipid
nanoparticles. Ther Deliv. 2016;7:319–334. doi:10.4155/tde-
2016-0006
[24] Edwards DK, Jasny E, Yoon H, et al. Adjuvant effects of a
sequence-engineered mRNA vaccine: translational profiling
demonstrates similar human and murine innate response. J
Transl Med. 2017;15:1. doi:10.1186/s12967-016-1111-6
[25] Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a
transformative technology for vaccine development to
control infectious diseases. Mol Ther. 2019;27:757–772.
doi:10.1016/j.ymthe.2019.01.020
[26] Maruggi G, Chiarot E, Giovani C, et al. Immunogenicity and
protective efficacy induced by self-amplifying mRNA
vaccines encoding bacterial antigens. Vaccine. 2017;35:361–
368. doi:10.1016/j.vaccine.2016.11.040
[27] Heine A, Juranek S, Brossart P. Clinical and immunological
effects of mRNA vaccines in malignant diseases. Mol Cancer.
2021;20:52. doi:10.1186/s12943-021-01339-1
[28] Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of
COVID-19 RNA vaccine BNT162b1 in adults. Nature.
2020;586:589–593. doi:10.1038/s41586-020-2639-4
[29] Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of
an inactivated SARS-CoV-2 vaccine in Chinese adults aged
18–59 years: a phase I randomized, double-blinded,
controlled trial. Vaccine. 2021;39:2746–2754.
doi:10.1016/j.vaccine.2021.04.006
[30] Walsh EE, Frenck RW, Falsey AR, et al. Safety and
immunogenicity of two RNA-based Covid-19 vaccine
candidates. N Engl J Med. 2020;383:2439–2450.
doi:10.1056/NEJMoa2027906
[31] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy
of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med.
2020;383:2603–2615. doi:10.1056/NEJMoa2034577
[32] Ji RR, Qu Y, Zhu H, et al. BNT162b2 vaccine encoding the
SARS-CoV-2 P2 S protects transgenic hACE2 mice against
COVID-19. Vaccines (Basel). 2021;9:324.
[33] Chen N, Xia P, Li S, et al. RNA sensors of the innate immune
system and their detection of pathogens. IUBMB Life.
2017;69:297–304. doi:10.1002/iub.1625
[34] Kowalczyk A, Doener F, Zanzinger K, et al. Self-adjuvanted
mRNA vaccines induce local innate immune responses that
lead to a potent and boostable adaptive immunity. Vaccine.
2016;34:3882–3893. doi:10.1016/j.vaccine.2016.05.046
[35] Kell AM, Gale M. RIG-I in RNA virus recognition. Virology.
2015;479–480:110–121. doi:10.1016/j.virol.2015.02.017
[36] Saito T, Gale M. Differential recognition of double-stranded
RNA by RIG-I-like receptors in antiviral immunity. J Exp
Med. 2008;205:1523–1527. doi:10.1084/jem.20081210
[37] Loo YM, Gale M. Immune signaling by RIG-I-like receptors.
Immunity. 2011;34:680–692.
doi:10.1016/j.immuni.2011.05.003
[38] Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune
response to SARS-CoV-2 in lung epithelial cells. Cell Rep.
2021;34:108628. doi:10.1016/j.celrep.2020.108628
[39] Pollard C, Rejman J, De Haes W, et al. Type I IFN
counteracts the induction of antigen-specific immune
responses by lipid-based delivery of mRNA vaccines. Mol
Ther. 2013;21:251–259. doi:10.1038/mt.2012.202
[40] Lei X, Dong X, Ma R, et al. Activation and evasion of type I
interferon responses by SARS-CoV-2. Nat Commun.
2020;11:3810. doi:10.1038/s41467-020-17665-9
[41] Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for
COVID-19: what, why and how. Int J Biol Sci.
2021;17:1446–1460. doi:10.7150/ijbs.59233
[42] Chatzikleanthous D, O’Hagan DT, Adamo R. Lipid-based
nanoparticles for delivery of vaccine adjuvants and antigens:
toward multicomponent vaccines. Mol Pharm.
2021;18:2867–2888.
doi:10.1021/acs.molpharmaceut.1c00447
[43] Cubas R, Zhang S, Kwon S, et al. Virus-like particle (VLP)
lymphatic trafficking and immune response generation after
immunization by different routes. J Immunother.
2009;32:118–128. doi:10.1097/CJI.0b013e31818f13c4
[44] Lindgren G, Ols S, Liang F, et al. Induction of robust B cell
responses after influenza mRNA vaccination is accompanied
by circulating hemagglutinin-specific ICOS+ PD-1+
CXCR3+ T follicular helper cells. Front Immunol.
2017;8:1539. doi:10.3389/fimmu.2017.01539
[45] Cagigi A, Lore K. Immune responses induced by mRNA
vaccination in mice, monkeys and humans. Vaccines (Basel).
2021;9. doi:10.3390/vaccines9010061
[46] De Silva NS, Klein U. Dynamics of B cells in germinal
centres. Nat Rev Immunol. 2015;15:137–148.
doi:10.1038/nri3804
[47] Hewitt EW. The MHC class I antigen presentation pathway:
strategies for viral immune evasion. Immunology.
2003;110:163–169. doi:10.1046/j.1365-2567.2003.01738.x
[48] Blum JS, Wearsch PA, Cresswell P. Pathways of antigen
processing. Annu Rev Immunol. 2013;31:443–473.
doi:10.1146/annurev-immunol-032712-095910
[49] Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh
MG, Weissman D. Nanomaterial delivery systems for mRNA
vaccines. Vaccines (Basel). 2021;9:65.
[50] Rahman MM, Zhou N, Huang J. An overview on the
development of mRNA-based vaccines and their formulation
strategies for improved antigen expression in vivo. Vaccines
(Basel). 2021;9:244.
[51] Jackson NAC, Kester KE, Casimiro D, Gurunathan S,
DeRosa F. The promise of mRNA vaccines: a biotech and
industrial perspective. NPJ Vaccines. 2020;5:11.
doi:10.1038/s41541-020-0159-8
[52] Satarker S, Nampoothiri M. Structural proteins in severe
acute respiratory syndrome Coronavirus-2. Arch Med Res.
2020;51:482–491. doi:10.1016/j.arcmed.2020.05.012
[53] Naqvi AAT, Fatima K, Mohammad T, et al. Insights into
SARS-CoV-2 genome, structure, evolution, pathogenesis and

therapies: structural genomics approach. Biochim Biophys
Acta Mol Basis Dis. 2020;1866:165878.
doi:10.1016/j.bbadis.2020.165878
[54] Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute
respiratory syndrome Coronavirus-2 (SARS-CoV-2): an
update. Cureus. 2020;12:e7423. doi:10.7759/cureus.7423
[55] Dhama K, Patel SK, Sharun K, et al. SARS-CoV-2 jumping
the species barrier: zoonotic lessons from SARS, MERS and
recent advances to combat this pandemic virus. Travel Med
Infect Dis. 2020;37:101830.
doi:10.1016/j.tmaid.2020.101830
[56] Haque SM, Ashwaq O, Sarief A, Azad John Mohamed AK.
A comprehensive review about SARS-CoV-2. Future Virol.
2020;15:625–648. doi:10.2217/fvl-2020-0124
[57] Wei J, Hui A-M. Journey of the COVID-19 vaccine from 10
years to 1 year - reassured with real world evidence. Am J
Transl Med. 2021;5:1–12.
[58] Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first
approval. Drugs. 2021;81:495–501. doi:10.1007/s40265-
021-01480-7
[59] Anand P, Stahel VP. Review the safety of Covid-19 mRNA
vaccines: a review. Patient Saf Surg. 2021;15:20.
doi:10.1186/s13037-021-00291-9
[60] Anderson EJ, Rouphael NG, Widge AT, et al. Safety and
immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in
older adults. N Engl J Med. 2020;383:2427–2438.
doi:10.1056/NEJMoa2028436
[61] Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos
AB, Prado EO. SARS-CoV-2 vaccines strategies: a
comprehensive review of phase 3 candidates. NPJ Vaccines.
2021;6:28. doi:10.1038/s41541-021-00292-w
[62] Roth N, Schön J, Hoffmann D, et al. CV 2 CoV, an enhanced
mRNA based SARS-CoV-2 vaccine candidate, supports
higher protein expression and improved immunogenicity in
rats. 2021. Available from
https://www.biorxiv.org/content/10.1101/2021.05.13.44373
4v1. Accessed December 02, 2021.
[63] Rauch S, Roth N, Schwendt K, et al. mRNA-based SARS-
CoV-2 vaccine candidate CVnCoV induces high levels of
virus-neutralising antibodies and mediates protection in
rodents. NPJ Vaccines. 2021;6:57. doi:10.1038/s41541-021-
00311-w
[64] Kremsner PG, Guerrero RA, Arana E, et al.Efficacy and
Safety of the CVnCoV SARS-CoV-2 mRNA vaccine
candidate: results from Herald, a phase 2b/3, randomised,
observer-blinded, placebo-controlled clinical trial in ten
countries in Europe and Latin America. Lancet. 2021
[65] Zhang NN, Li X-F, Deng Y-Q, et al. A thermostable mRNA
vaccine against COVID-19. Cell. 2020;182:1271–1283
e1216. doi:10.1016/j.cell.2020.07.024
[66] Granados-Riveron JT, Aquino-Jarquin G. Engineering of the
current nucleoside-modified mRNA-LNP vaccines against
SARS-CoV-2. Biomed Pharmacother. 2021;142:111953.
doi:10.1016/j.biopha.2021.111953
[67] Laczko D, Hogan MJ, Toulmin SA, et al. A single
immunization with nucleoside-modified mRNA vaccines
elicits strong cellular and humoral immune responses against
SARS-CoV-2 in mice. Immunity. 2020;53:724–732 e727.
doi:10.1016/j.immuni.2020.07.019
[68] Samantaray, M. U. S., & Santra, M. P. (2021). Human
Adenovirus Serotypes Efficiently Transducing HEK293
Cells: An In Vitro Propagation of HAdv. International
Journal for Research in Applied Sciences and Biotechnology,
8(5), 17-21. https://doi.org/10.31033/ijrasb.8.5.3
[69] Mr. Utkalendu Suvendusekhar Samantaray, & Ms.
Swapnarani Sethi. (2021). Isolation and Biochemical
Characterization of Indole-3-Acetic Acid (IAA) Produced in
Pseudomonas Sp. Isolated from Rhizospheric Soil.
International Journal for Research in Applied Sciences and
Biotechnology, 8(4), 1-14.
https://doi.org/10.31033/ijrasb.8.4.1
[70] Mr. Utkalendu Suvendusekhar Samantaray, & Ms. Tanima
Singh. (2021). Optimization of Modified Murashige and
Skoog (MS) Medium Promoting Efficient Callus Induction in
Zinnia elegans. International Journal for Research in Applied
Sciences and Biotechnology, 8(3), 202-211.
[71] Samantaray, M. U. suvendusekhar, & Tripathy, M. S. (2021).
Quantitative Analysis of Nutrients and Biochemical
Evaluation in Pomfret Fish (Pampus argenteus) During
Frozen Storage. International Journal for Research in Applied
Sciences and Biotechnology, 8(3), 180-195.
[72] Samantaray, M. U. suvendusekhar, & Patro, M. A. (2021).
Comparative Study of Antioxidant Activity and ROS
Production Profile among Clarias batrachus, Cirrhinus reba,
Channa punctatus (Freshwater Species). International Journal
for Research in Applied Sciences and Biotechnology, 8(3),
160-179. https://doi.org/10.31033/ijrasb.8.3.22
[73] Samantaray, M. U. S., & Sahu, S. (2021). Characterization
and Cellulase Production Activity of different Aspergillus Sp.
Isolated from “Puri, Odisha” Marine Fungal Strains.
International Journal for Research in Applied Sciences and
Biotechnology, 8(3), 71-87.
[74] Mr. Utkalendu Suvendusekhar Samantaray, Ms. Ankita
Mishra, & Yengkhom D. Singh. (2020). Biosynthesis and
Antimicrobial activities of Silver Nanoparticles (AgNPs) by
using Leaf Extracts of Tagetes erecta (Marigold) and Tridax
procumbens (Tridax). International Journal for Research in
Applied Sciences and Biotechnology, 7(6), 209-226.
[75] Samantaray US, Sahu S, Patro A, Tripathy S, Sethi S,
Phytochemicals: A novelantiviraltherapeutic approach for
Prevention of lung injury and respiratory infection during
COVID 19,SPR, Volume 2, issue 1, Page No.: 528-540. DOI:
https://doi.org/10.52152/spr/2021.177

mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery

Similar to mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery (20)

More from AI Publications

More from AI Publications (20)

Recently uploaded

Recently uploaded (20)

mRNA vaccines against emerging infectious diseases; A challenging approach of novel vaccine discovery